We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 379

Intellectual property weekly abstracts bulletin
  • Borden Ladner Gervais LLP
  • Canada
  • June 17 2013

Although the Court of Appeal had split 2-1, the Supreme Court refused Takeda's application for leave as well as the motion to intervene by Canada's


Section 8 damages claim allowed; infringement not proven
  • Borden Ladner Gervais LLP
  • Canada
  • September 18 2013

Apotex claimed damages from Pfizer pursuant to s. 8 of the Patented Medicines (Notice of Compliance) Regulations (the NOC Regulations). The hearing


Patent not eligible for listing: patent claiming one medicinal ingredient,but directed to a fixed-dose combination of medicines
  • Borden Ladner Gervais LLP
  • Canada
  • October 15 2014

This was an appeal from two decisions for three proceedings before Prothonotary Milczynski, in which she determined that a patent could not be listed


NOC proceedings
  • Borden Ladner Gervais LLP
  • Canada
  • March 25 2013

The Federal Court found Teva’s allegations of invalidity were not justified for Novartis’ narrow compound patent, while the allegations against


Motion for default judgment denied without affidavit evidence
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2013

The Plaintiffs brought a motion for default judgment after no Statement of Defence was filed and no response to the Request to Admit was provided. The


Other industry news
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2013

Health Canada has released of the Therapeutic Products Directorate Statistical Report 20122013 for the Patented Medicines (Notice of Compliance


Prohibition granted re the compound patent; dismissed re use and polymorph patents
  • Borden Ladner Gervais LLP
  • Canada
  • May 30 2014

This NOC proceeding deals with challenges to three patents, a compound patent, a use patent and a polymorph patent


Product specificity is the same for different types of claims in listing on the Patent Register
  • Borden Ladner Gervais LLP
  • Canada
  • May 30 2014

Teva brought a motion pursuant to section 6(5)(a) of the Patented Medicines (Notice of Compliance) Regulations relating to the listing of a patent on


Court bifurcates determination of Start Date for section 8 action
  • Borden Ladner Gervais LLP
  • Canada
  • May 30 2014

This is an action commenced pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations. Pfizer counterclaimed against Apotex


ss. 53(2) of the Patent Act is a shield, not a sword
  • Borden Ladner Gervais LLP
  • Canada
  • October 21 2013

Hoffmann-La Roche was denied the opportunity to correct a single word error in a patent’s disclosure pursuant to ss.53(2) of the Patent Act. The